The Shelburne Group | IACTA Pharmaceuticals
21285
portfolio_page-template-default,single,single-portfolio_page,postid-21285,ajax_fade,page_not_loaded,,select-theme-ver-4.2,vertical_menu_enabled,no_animation_on_touch,wpb-js-composer js-comp-ver-8.0.1,vc_responsive
 

IACTA Pharmaceuticals

IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. They are dedicated to treating diseases, advancing technology and improving patient outcomes.

Their lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye. Using licensed proprietary Molecular Envelope Technology (MET) from the research stage company Nanomerics, Ltd., this unique nanotechnology allows a hydrophobic drug to be encapsulated and delivered to the tissues of the eye with favorable tissue permeation.

They are developing this innovative drug as a new treatment option for patients with dry eye.

Visit Client Website